Correspondence 0001193125-24-198313 from Nuvation Bio Inc. (NUVB, NUVB-WT) (CIK 0001811063) (NUVB)
Nuvation Bio Inc. (NUVB, NUVB-WT) (CIK 0001811063)
Date: Aug. 12, 2024 · CIK: 0001811063 · Accession: 0001193125-24-198313
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281255
Letter
NUVATION BIO INC.
1500 Broadway, Suite 1401
New York, New York 10036
August 12, 2024
VIA EDGAR
Division of Corporation Finance
Office of Life Sciences
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
RE: Nuvation Bio Inc.
Registration Statement on Form S-3
File No. 333-281255
Ladies and Gentlemen:
Nuvation Bio Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) cause the Registrant’s above-referenced Registration Statement on Form S-3 to become effective on August 14, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth L. Guernsey and John T. McKenna of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth L. Guernsey of Cooley LLP, counsel to the Registrant, at (415) 693-2091, or in his absence, John T. McKenna at (650) 843-5059.
Very truly yours,
NUVATION BIO INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP NUVATION BIO INC. 1500 Broadway, Suite 1401 New York, New York 10036 August 12, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Nuvation Bio Inc. Registration Statement on Form S-3 File No. 333-281255 Ladies and Gentlemen: Nuvation Bio Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) cause the Registrant’s above-referenced Registration Statement on Form S-3 to become effective on August 14, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth L. Guernsey and John T. McKenna of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth L. Guernsey of Cooley LLP, counsel to the Registrant, at (415) 693-2091, or in his absence, John T. McKenna at (650) 843-5059. Very truly yours, NUVATION BIO INC. By: /s/ David Hung, M.D. Name: David Hung, M.D. Title: Chief Executive Officer cc: Moses Makunje, Nuvation Bio Inc. Kenneth L. Guernsey, Cooley LLP John T. McKenna, Cooley LLP